MGF and IGF-1 Ec: Muscle Satellite Cell Activation and Repair Research

Mechano-Growth Factor (MGF) is a splice variant of the IGF-1 gene produced specifically in mechanically stressed skeletal muscle, cardiac muscle, and bone. Unlike systemic IGF-1 LR3 produced primarily by the liver under GH stimulation, MGF acts in an autocrine/paracrine fashion with a functionally distinct role in muscle repair.

Splice Variant Biology and the E-Peptide

The IGF-1 gene produces multiple isoforms through alternative splicing. The MGF isoform (IGF-1Ec in humans) includes a unique 24-amino acid C-terminal E-peptide that is absent from the dominant liver isoform IGF-1Ea. Crucially, Yang SY and Goldspink G (*FEBS Letters*, 2002) demonstrated that a synthetic 24-amino acid C-terminal E-peptide fragment activates satellite cells independently of the IGF-1 receptor — establishing an IGF1R-independent mechanism unique to MGF.

Satellite Cell Activation: The Primary Role

The functional distinction between MGF and IGF-1 LR3:

• MGF E-peptide: Activates quiescent satellite cells (G0 → G1), driving proliferation of the muscle stem cell pool — acts first in the repair cascade
• IGF-1 Ea (and its analogue IGF-1 LR3): Acts through IGF1R-Akt/mTOR to drive differentiation of activated satellite cells into mature myotubes — acts later

Philippou A et al. (*Hormones*, 2007) measured MGF mRNA in human muscle after heavy resistance exercise, finding peak at 48h post-exercise. IGF-1Ea mRNA peaked at 96-120h and remained elevated for 168h — directly confirming the sequential model.

Cardiac Research

Carpenter V et al. (*Biochemical and Biophysical Research Communications*, 2008) showed that MGF E-peptide reduced cardiomyocyte apoptosis at the infarct border zone by ~40% vs vehicle in mouse MI models — and that IGF-1 receptor antagonism did not block this effect, confirming IGF1R-independent E-peptide signalling.

PEGylated MGF

Native MGF E-peptide has a plasma half-life of ~2-5 minutes. PEGylated MGF extends this to ~5-7 days, enabling weekly dosing. In comparison studies, PEG-MGF at 1 mg/kg once weekly produced satellite cell activation and fibre cross-sectional area increases equivalent to daily native MGF E-peptide dosing.

Intramuscular vs Systemic Administration

Published studies use intramuscular injection into target muscle groups (200-500 mcg/kg) for native MGF because systemic injection leads to peptide degradation before reaching target tissue. PEG-MGF can be administered subcutaneously due to extended half-life.

MGF is a research peptide not approved for human use. All dosing references are from preclinical animal studies.

<!-- deep-links-v1 -->

Related Muscle and Growth Factor Peptides

Mechano Growth Factor sits within a broader anabolic peptide research space. IGF-1 DES, the binding-protein-resistant truncated IGF-1 form, provides local tissue anabolism without the systemic IGF-BP sequestration that limits full-length IGF-1. PEG-MGF, the pegylated MGF analogue, extends the satellite cell activation window that native MGF's short half-life limits. ACE-031 and Follistatin-344 work from the opposite direction, removing the myostatin-mediated brake on muscle growth. Bolamin, a tetrapeptide bone-and-muscle bioregulator, is studied for connective tissue anabolic support in musculoskeletal research settings.